Eversana and Waltz Health Merge to Revolutionize Pharmaceutical Pricing and Access

In a significant move set to reshape the pharmaceutical industry landscape, health tech company Waltz Health has announced its merger with Eversana, forming a combined pharmaceutical pricing platform. The deal, announced on August 26, 2025, aims to address longstanding challenges in drug pricing and patient access.

A Unified Approach to Drug Commercialization

The merger brings together Waltz Health's proprietary drug marketplaces and direct-to-payer model with Eversana's global pharmaceutical commercialization platform. This strategic combination is positioned to tackle misaligned incentives in the drug supply chain and improve patient access to medications.

Mark Thierer, CEO and co-founder of Waltz Health, who will lead the new combined company as CEO, stated, "This is a pivotal moment for the healthcare industry. By combining Eversana's pharma services with Waltz's technology-enabled payer solutions, we're creating a unified platform that connects life sciences innovation directly to the organizations and individuals we're meant to serve."

The integrated platform will offer a comprehensive suite of solutions, leveraging Eversana's expertise in pharmaceutical commercialization and Waltz Health's advanced technology stack. This "turnkey" solution for drugmakers aims to streamline the process of reaching patients while optimizing pricing strategies.

Targeting High-Cost Medications and Improving Patient Outcomes

A key focus of the merged entity will be driving down the cost of expensive specialty pharmacy products, including GLP-1s. The combined platform utilizes net-price models, copay optimization tools, and pharmacy routing to enhance medication adherence and reduce the likelihood of patients abandoning their prescribed treatments.

"This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step," Thierer emphasized. The merger comes at a time when pharmaceutical pricing is under intense scrutiny from policymakers and patient advocates, positioning the new company to play a crucial role in balancing innovation with affordability and access.

Leadership and Future Outlook

While financial terms of the deal were not disclosed, the merger brings together significant industry experience. Mark Thierer, a healthcare veteran with a background in pharmacy benefit management, will lead the combined organization. Jim Lang, Eversana's CEO, will serve as a board member.

Thierer concluded, "Together, we are launching a new-to-the-world model that directly connects manufacturers to patients and payers, delivering significant cost savings and improved patient outcomes to the healthcare system." As the pharmaceutical industry continues to evolve, this merger represents a bold step towards addressing longstanding challenges in drug pricing and patient access.